In many cases, the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT) can be identified before pregnancy using genetic testing. The reason many women are not diagnosed this early is that they are not offered this screening unless a problem has already occurred or a previous pregnancy has been affected.
What is FNAIT?
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare but serious condition in which a pregnant mother’s immune system produces antibodies against the platelets of her fetus. This occurs when a fetus inherits platelet antigens from the father that are not compatible with the mother, typically involving a protein called human platelet antigen (HPA). The mother’s immune system recognizes the fetal platelets as foreign, attacking and destroying them, leading to low platelet levels (thrombocytopenia) in the fetus or newborn.
Understanding how FNAIT develops
FNAIT occurs when the fetus inherits a platelet antigen from the other biological parent that the mother doesn’t have. The most common trigger is the human platelet antigen HPA-1a. If a pregnant woman lacks this antigen but the fetus inherits it, the immune system may recognize it as foreign and produce antibodies against it. These antibodies can cross the placenta and destroy fetal platelets.
FNAIT can cause severe complications before anyone knows the risk exists. This unpredictability is why early detection has become a major focus of research.
Can women be screened for FNAIT before pregnancy?
In theory, FNAIT risk can be determined before pregnancy. A simple blood test can show whether someone carries platelet antigens such as HPA-1a. If testing reveals they do not carry the antigen, further testing of their partner could determine whether a future baby might inherit it.
Learn more about FNAIT testing and diagnosis
However, testing for FNAIT is not part of standard pregnancy screening and is not widely accessible. One major reason is that the condition is relatively rare, occurring in one in 800 to one in 2,000 live births. In general, health systems seek to balance the cost and logistics of screening large populations against the number of cases that would be detected.
As a result, testing for FNAIT is now typically offered only if a patient has already raised concerns, such as those who have had a previously affected pregnancy.
The future of FNAIT screening
Interest in broader genetic testing for FNAIT risk is growing, as early detection means families and doctors can plan preventive care and begin treatment sooner. Specialists around the world are exploring cost-effective antenatal screening programs for FNAIT, although more research is needed.
For now, FNAIT risk assessment before pregnancy is possible but not routine. As research continues, earlier detection may help prevent unexpected complications and support safer pregnancies for families at risk.
Sign up here to get the latest news, perspectives, and information about FNAIT sent directly to your inbox. Registration is free and only takes a minute.
